Her-2 Neu Expression in Endometrial Carcinoma | ||||
| The Medical Journal of Cairo University | ||||
| Article 10, Volume 86, March, March 2018, Page 69-76 PDF (844.62 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjcu.2018.55033 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| AFAF T. ELNASHAR, M.D.; NOHA ED. HASSAB ELNABY, M.D.; ASMAA A. ABDELLATEF, M.D.; MOHAMED N. SALEM, M.D. | ||||
| The Departments of Pathology* and Obstetrics & Gynaecology**, Faculty of Medicine, Sohag University | ||||
| Abstract | ||||
| Abstract Introduction: Endometrial cancer formed 0.004 of the tumors in Egypt. Detection of high grade tumors from the low-grade ones is mandatory for survival of the patients. Aim of the Work: The use of immunohistochemical tech-nique to detect the expression of Her-2 neu in endometrial carcinomas. Material and Methods: Fifty cases of endometrial carci-noma (37 endometrioid, 10 serous, 1 clear cell and 2 undif-ferentiated carcinomas) were stained with Her-2 neu and its immunoexpression results were evaluated statistically using Chi-square and t-test. Results: Her-2 neu was expressed in (76%) 38/50 cases with statistically significant relation between Her-2 expression and both grade of the tumor p<0.013 and stage p<0.05. Although Her-2 immunostaining was not correlated with tumor histological type p<0.088. Conclusions: Her-2 neu could be used to detect the low-grade, early-stages, endometrial carcinomas from the more aggressive high-grade endometrial carcinomas for therapy modulation. | ||||
| Keywords | ||||
| Her-2 neu – Endometrial carcinoma – Immuno-histochemical expression | ||||
|
Statistics Article View: 199 PDF Download: 392 |
||||
